Retroviral vectors are widely used for preclinical and clinical applications. Unlike many of the other types of vectors currently being developed for gene therapy, retroviral vectors are able to genetically modify cells stably without perturbing cell growth. Retroviral vectors based on murine retroviruses are well suited for ex vivo applications where the cells are rapidly dividing. In particular, retroviral viral vectors have been used for a variety of ex vivo gene therapy approaches for treating genetic diseases such as Gaucher and severe combined immunodeficiency (SCID) and for acquired diseases such as cancer and arthritis. However, recent advances in the production of retroviral vectors have allowed for their use in vivo such as for the treatment of cancer and human immunodeficiency virus. The ability to target retroviral vectors to specific cell types will also increase the utility of high titer retroviral vectors for in vivo applications. Clearly retroviral vectors have been extremely useful for both preclinical and clinical gene therapy studies, and it is likely that they will continue to be utilized for ex vivo and in vivo strategies in the future.
|Original language||English (US)|
|Title of host publication||Advances in Virus Research|
|Publisher||Academic Press Inc.|
|Number of pages||19|
|ISBN (Print)||0120398559, 9780120398553|
|State||Published - 2000|
|Name||Advances in Virus Research|
Bibliographical noteFunding Information:
The authors would like to thank Bruce Baldwin for technical assistance. This work was supported in part by Public Health Service Grants CA59371, CA73743, AI43666, and DK44935 to PDR.
Copyright 2020 Elsevier B.V., All rights reserved.